300142 沃森生物
已收盘 06-17 15:00:00
资讯
新帖
简况
沃森生物:爱森泽生物技术(昆明)有限公司属于公司合并财务报表范围内的子公司
证券之星 · 06-17 20:52
沃森生物:爱森泽生物技术(昆明)有限公司属于公司合并财务报表范围内的子公司
沃森生物:公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
证券之星 · 06-17 11:36
沃森生物:公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中
沃森生物:公司四价流脑结合疫苗目前处于III期临床研究阶段
证券之星 · 06-17 11:33
沃森生物:公司四价流脑结合疫苗目前处于III期临床研究阶段
沃森生物(300142.SZ):13价肺炎球菌多糖结合疫苗印度尼西亚2p+1免疫程序Ⅲ期临床试验获得临床试验报告
智通财经 · 06-16 16:26
沃森生物(300142.SZ):13价肺炎球菌多糖结合疫苗印度尼西亚2p+1免疫程序Ⅲ期临床试验获得临床试验报告
沃森生物:山西制造基地规划主要是公司肠道微生态业务中核心菌群疗法的基石功能群营养产品
证券之星 · 06-12
沃森生物:山西制造基地规划主要是公司肠道微生态业务中核心菌群疗法的基石功能群营养产品
沃森生物:公司2026年度向特定对象发行A股股票的各项工作在按计划持续推进中
证券之星 · 06-10
沃森生物:公司2026年度向特定对象发行A股股票的各项工作在按计划持续推进中
沃森生物:优化核心自主产品产销,拓展海内外市场
证券之星 · 06-09
沃森生物:优化核心自主产品产销,拓展海内外市场
6月8日沃森生物跌5.07%,疫苗ETF嘉实基金重仓该股
证券之星 · 06-08
6月8日沃森生物跌5.07%,疫苗ETF嘉实基金重仓该股
沃森生物:公司持有上海柯君医药科技有限公司11.3852%股权
证券之星 · 06-01
沃森生物:公司持有上海柯君医药科技有限公司11.3852%股权
沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施
证券之星 · 06-01
沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施
沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施
证券之星 · 05-19
沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施
沃森生物:利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗
证券之星 · 05-11
沃森生物:利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗
股市必读:沃森生物(300142)5月8日披露最新机构调研信息
证券之星 · 05-11
股市必读:沃森生物(300142)5月8日披露最新机构调研信息
沃森生物:5月8日接受机构调研,中金公司研究部、Dymon Asia参与
证券之星 · 05-09
沃森生物:5月8日接受机构调研,中金公司研究部、Dymon Asia参与
沃森生物:本次发行相关事项的生效和完成尚需国家市场监督管理总局经营者集中申报审查通过(如需)、深圳证券交易所审核通过并需经中国证监会同意注册等其他必需的行政审批机关批准后方可实施
证券之星 · 05-07
沃森生物:本次发行相关事项的生效和完成尚需国家市场监督管理总局经营者集中申报审查通过(如需)、深圳证券交易所审核通过并需经中国证监会同意注册等其他必需的行政审批机关批准后方可实施
每周股票复盘:沃森生物(300142)Q1净利增4082.41%
证券之星 · 05-03
每周股票复盘:沃森生物(300142)Q1净利增4082.41%
4月28日沃森生物涨7.53%,疫苗ETF嘉实基金重仓该股
证券之星 · 04-28
4月28日沃森生物涨7.53%,疫苗ETF嘉实基金重仓该股
沃森生物最新公告:第一季度净利润同比增长4082.41%
证券之星 · 04-27
沃森生物最新公告:第一季度净利润同比增长4082.41%
沃森生物:公司通过新冠mRNA疫苗的研发与合作方一起建立了mRNA疫苗技术平台
证券之星 · 04-16
沃森生物:公司通过新冠mRNA疫苗的研发与合作方一起建立了mRNA疫苗技术平台
沃森生物:持续深化营销体系改革
证券之星 · 04-15
沃森生物:持续深化营销体系改革
加载更多
公司概况
公司名称:
云南沃森生物技术股份有限公司
所属行业:
医药制造业
上市日期:
2010-11-12
主营业务:
云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业,也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。
发行价格:
95.00
{"stockData":{"symbol":"300142","market":"SZ","secType":"STK","nameCN":"沃森生物","latestPrice":12.01,"timestamp":1781679831000,"preClose":12.14,"halted":0,"volume":52361292,"delay":0,"changeRate":-0.0107,"floatShares":1577000000,"shares":1599000000,"eps":0.1787,"marketStatus":"已收盘","change":-0.13,"latestTime":"06-17 15:00:00","open":11.98,"high":12.22,"low":11.9,"amount":630000000,"amplitude":0.0264,"askPrice":12.02,"askSize":936,"bidPrice":12.01,"bidSize":578,"shortable":0,"etf":0,"ttmEps":0.1787,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781746200000},"marketStatusCode":5,"adr":0,"adjPreClose":12.14,"symbolType":"stock","openAndCloseTimeList":[[1781659800000,1781667000000],[1781672400000,1781679600000]],"highLimit":13.35,"lowLimit":10.93,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1599348541,"isCdr":false,"pbRate":2.62,"roa":"--","peRate":67.207611,"roe":"1.41%","epsLYR":0.1111,"committee":-0.271518,"marketValue":19208000000,"turnoverRate":0.0332,"status":1,"floatMarketCap":18939000000},"requestUrl":"/m/hq/s/300142","defaultTab":"news","newsList":[{"id":"2644746774","title":"沃森生物:爱森泽生物技术(昆明)有限公司属于公司合并财务报表范围内的子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746774","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644746774?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:52","pubTimestamp":1781700763,"startTime":"0","endTime":"0","summary":"3)是否已纳入公司合并报表并单独披露?爱森泽生物技术(昆明)有限公司作为公司光生物合成技术与产业化的平台,聚焦于医药健康天然产物的光生物合成,是公司在生物制造领域业务布局的重要组成部分,属于公司合并财务报表范围内的子公司。关于爱森泽生物技术(昆明)有限公司经营管理和业绩的相关信息请以公司披露的定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700039477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","300142","BK0070","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644379714","title":"沃森生物:公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2644379714","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644379714?lang=zh_cn&edition=full","pubTime":"2026-06-17 11:36","pubTimestamp":1781667369,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)06月16日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,你公司的定增工作是不是终止了,为什么不公告!沃森生物回复:尊敬的投资者,您好!公司2026年度向特定对象发行A股股票的各项工作目前在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施,后续进展情况还请持续关注公司披露的信息。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700016948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","399300","BK0239","159982","BK0070","300142","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644797986","title":"沃森生物:公司四价流脑结合疫苗目前处于III期临床研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2644797986","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644797986?lang=zh_cn&edition=full","pubTime":"2026-06-17 11:33","pubTimestamp":1781667231,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物06月16日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,关于四价流脑结合疫苗:1)Ⅲ 期临床总结报告是否已正式定稿并提交 CDE?四价流脑结合疫苗迟迟没有批准的原因是否是数据很差沃森生物回复:尊敬的投资者,您好!公司四价流脑结合疫苗目前处于III期临床研究阶段,公司将按照国家对于注册临床试验的有关程序和要求推进相关工作。关于产品的后续进展情况请持续关注公司披露的信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700016768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0077","BK0070","BK0046","BK0239","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643737357","title":"沃森生物(300142.SZ):13价肺炎球菌多糖结合疫苗印度尼西亚2p+1免疫程序Ⅲ期临床试验获得临床试验报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2643737357","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643737357?lang=zh_cn&edition=full","pubTime":"2026-06-16 16:26","pubTimestamp":1781598369,"startTime":"0","endTime":"0","summary":"智通财经APP讯,沃森生物 发布公告,公司子公司玉溪沃森生物技术有限公司于近日收到13价肺炎球菌多糖结合疫苗在印度尼西亚开展的“2p+1”免疫程序Ⅲ期临床试验报告。玉溪沃森于2023 年9月收到印度尼西亚食品药品监督管理局签发的本疫苗的Ⅲ 期临床试验批件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK0046","BK0239","BK0070","300142","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642258077","title":"沃森生物:山西制造基地规划主要是公司肠道微生态业务中核心菌群疗法的基石功能群营养产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2642258077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642258077?lang=zh_cn&edition=full","pubTime":"2026-06-12 08:46","pubTimestamp":1781225169,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物06月11日在投资者关系平台上答复投资者关心的问题。山西拜诺作为公司微生态与特医产业化核心基地,请问:1)山西拜诺在微生态活菌制剂与特医产品中的战略定位,与无锡曼诺三合如何协同?2)洪洞基地产能规划、技术路线及核心产品管线?山西制造基地的规划主要是公司肠道微生态业务中核心菌群疗法的基石功能群营养产品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061200005812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","300142","BK0046","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642105446","title":"沃森生物:公司2026年度向特定对象发行A股股票的各项工作在按计划持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2642105446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642105446?lang=zh_cn&edition=full","pubTime":"2026-06-10 16:03","pubTimestamp":1781078596,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)06月10日在投资者关系平台上答复投资者关心的问题。投资者提问:公司 20 亿定增自 4 月 3 日股东会通过后至今未提交深交所,请问材料准备是否遇阻?预计受理时间?请详细说明原因。沃森生物回复:尊敬的投资者,您好!公司2026年度向特定对象发行A股股票的各项工作在按计划持续推进中,本次发行后续还需要经深圳证券交易所审核通过并经中国证监会同意注册等必需的行政审批后方可实施,后续进展情况还请持续关注公司披露的信息。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000026230.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0077","300142","159982","BK0046","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642146040","title":"沃森生物:优化核心自主产品产销,拓展海内外市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2642146040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642146040?lang=zh_cn&edition=full","pubTime":"2026-06-09 20:51","pubTimestamp":1781009484,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物06月08日在投资者关系平台上答复投资者关心的问题。公司将不断优化核心自主产品的生产和销售工作,坚持产品质量不松懈,深耕国内市场,拓展国际市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900036551.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0070","BK0077","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641107795","title":"6月8日沃森生物跌5.07%,疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641107795","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641107795?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:57","pubTimestamp":1780909054,"startTime":"0","endTime":"0","summary":"证券之星消息,6月8日沃森生物跌5.07%创60日新低,收盘报11.23元,换手率3.72%,成交量58.72万手,成交额6.7亿元。重仓沃森生物的前十大公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共11家,其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060800022543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0077","562860","BK0046","300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640693190","title":"沃森生物:公司持有上海柯君医药科技有限公司11.3852%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2640693190","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640693190?lang=zh_cn&edition=full","pubTime":"2026-06-01 15:48","pubTimestamp":1780300087,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,贵司投资柯君医药为什么不公告?本次牵头柯君医药融资,贵司持股占比多少?沃森生物回复:尊敬的投资者,您好!根据《深圳证券交易所创业板股票上市规则》《公司章程》及公司《对外投资决策程序与规则》的相关规定,本次投资事宜经公司总裁办公会审议通过后实施。根据工商登记信息显示,本次投资于2026年4月完成了工商变更登记,公司持有上海柯君医药科技有限公司11.3852%股权,上海柯君医药科技有限公司现为公司的参股公司。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100018683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300142","BK0070","BK0077","159938","BK1574","BK0046","BK1515","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640939782","title":"沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2640939782","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640939782?lang=zh_cn&edition=full","pubTime":"2026-06-01 15:33","pubTimestamp":1780299215,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问:沃森生物近期股价一直低迷,公司的分红也一直推不出来,目前具体的分红时间定下来了嘛?公司的肠道益生菌减肥产品啥时候上市沃森生物回复:尊敬的投资者,您好!公司已于2026年4月29日召开2025年年度股东会,审议通过2025年年度权益分派事项,公司将在股东会审议通过后2个月内完成本次权益分派的实施,具体实施时间请关注公司后续披露的公告。谢谢!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100017161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0070","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636348888","title":"沃森生物:公司将在股东会审议通过后2个月内完成本次权益分派的实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2636348888","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636348888?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:42","pubTimestamp":1779151336,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司何时分红沃森生物回复:尊敬的投资者,您好!公司已于2026年4月29日召开2025年年度股东会,审议通过2025年年度权益分派事项,公司将在股东会审议通过后2个月内完成本次权益分派的实施,具体实施时间请关注公司后续披露的公告。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900009174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","300142","BK0239","BK0077","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634703409","title":"沃森生物:利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2634703409","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634703409?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:42","pubTimestamp":1778488933,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物05月11日在投资者关系平台上答复投资者关心的问题。在疫苗产品研发上,公司一方面将持续加强目前已上市品种的产品升级,开发更高价次肺炎球菌多糖结合疫苗、更高价次脑膜炎球菌疫苗、更高价次HPV疫苗,并进一步扩大适用人群范围;另一方面将不断加快创新性疫苗的研发布局,同时,利用已上市或处于临床研究阶段的疫苗产品大力开发针对婴幼儿的联合疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0046","BK0077","BK0070","300142","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634425515","title":"股市必读:沃森生物(300142)5月8日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2634425515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634425515?lang=zh_cn&edition=full","pubTime":"2026-05-11 01:48","pubTimestamp":1778435296,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘,沃森生物报收于13.35元,上涨1.52%,换手率4.95%,成交量78.07万手,成交额10.45亿元。当日关注点来自交易信息汇总:5月8日主力资金净流入1834.41万元,游资资金同步净流入,散户资金呈净流出态势。来自机构调研要点:5月8日公司召开电话会议,副总裁、董事会秘书等高管参与交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100000869.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0070","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634495239","title":"沃森生物:5月8日接受机构调研,中金公司研究部、Dymon Asia参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2634495239","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634495239?lang=zh_cn&edition=full","pubTime":"2026-05-09 09:03","pubTimestamp":1778288597,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年5月8日沃森生物发布公告称公司于2026年5月8日接受机构调研,中金公司研究部杨一正、Dymon AsiaBen Wei Wang Pei参与。沃森生物2026年一季报显示,一季度公司主营收入4.44亿元,同比下降3.98%;归母净利润1.11亿元,同比上升4082.41%;扣非净利润1.14亿元,同比上升1089.2%;负债率29.79%,投资收益-23.82万元,财务费用359.15万元,毛利率68.47%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900004425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","BK0276","LU1781817850.SGD","BK1147","601995","BK0239","300142","LU0359201612.USD","LU2663582299.SGD","BK0046","LU0359201885.HKD","LU1580142542.USD","LU1508157978.USD","03908","LU0359202008.SGD","BK1564","BK1501","BK1516","LU1023057109.AUD","SG9999002828.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633118072","title":"沃森生物:本次发行相关事项的生效和完成尚需国家市场监督管理总局经营者集中申报审查通过(如需)、深圳证券交易所审核通过并需经中国证监会同意注册等其他必需的行政审批机关批准后方可实施","url":"https://stock-news.laohu8.com/highlight/detail?id=2633118072","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633118072?lang=zh_cn&edition=full","pubTime":"2026-05-07 15:42","pubTimestamp":1778139733,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物(300142)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问:请问腾云新沃的投资款到位了吗?沃森生物回复:尊敬的投资者,您好!本次发行相关事项的生效和完成尚需国家市场监督管理总局经营者集中申报审查通过(如需)、深圳证券交易所审核通过并需经中国证监会同意注册等其他必需的行政审批机关批准后方可实施。敬请广大投资者注意投资风险。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700020344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142","BK0077","BK0239","BK0046","399001","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632670663","title":"每周股票复盘:沃森生物(300142)Q1净利增4082.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632670663","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632670663?lang=zh_cn&edition=full","pubTime":"2026-05-03 06:42","pubTimestamp":1777761735,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,沃森生物报收于13.0元,较上周的11.88元上涨9.43%。本周,沃森生物4月28日盘中最高价报13.61元。本周关注点来自业绩披露要点:沃森生物2026年一季报归母净利润1.11亿元,同比上升4082.41%。股本股东变化股东户数变动截至2026年3月31日,沃森生物股东户数为11.84万户,较2月28日减少319.0户,减幅0.27%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0077","BK0239","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630376329","title":"4月28日沃森生物涨7.53%,疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630376329","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630376329?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:33","pubTimestamp":1777365189,"startTime":"0","endTime":"0","summary":"证券之星消息,4月28日沃森生物涨7.53%,收盘报12.85元,换手率10.41%,成交量162.42万手,成交额21.22亿元。重仓沃森生物的前十大公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共11家,其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元,最新净值0.6836,较上一交易日上涨0.15%,近一年上涨13.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800049268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0070","562860","BK0239","300142","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630364349","title":"沃森生物最新公告:第一季度净利润同比增长4082.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630364349","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630364349?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:36","pubTimestamp":1777282608,"startTime":"0","endTime":"0","summary":"沃森生物公告称,2026年第一季度实现营业收入4.44亿元,同比下降3.98%;归属于上市公司股东的净利润为1.11亿元,同比增长4082.41%。业绩变动主要系公司根据行业情况及实际业务情况变更应收账款预期信用损失会计估计,导致应收账款坏账准备计提金额下降,以及本期转回坏账准备所致;同时,公司20价肺炎球菌多糖结合疫苗和新型冠状病毒变异株mRNA疫苗项目已达到资本化阶段,而上年同期处于费用化阶段,致使研发费用减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700032614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627126330","title":"沃森生物:公司通过新冠mRNA疫苗的研发与合作方一起建立了mRNA疫苗技术平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2627126330","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627126330?lang=zh_cn&edition=full","pubTime":"2026-04-16 11:48","pubTimestamp":1776311288,"startTime":"0","endTime":"0","summary":"从全球来看,mRNA创新技术平台历经数十年技术沉淀,打破了传统疫苗研发模式的限制,过去几年,全球创新疫苗企业借助该技术已累计创造了较高的商业价值。经过多年的持续投入,中国创新疫苗企业也已建立了自己的mRNA疫苗技术平台,部分疫苗企业已在多款mRNA疫苗上有研发布局。关于公司mRNA疫苗平台建设及相关产品的后续进展情况请持续关注公司的信息披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600018568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","300142","BK0046","BK0077","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627475367","title":"沃森生物:持续深化营销体系改革","url":"https://stock-news.laohu8.com/highlight/detail?id=2627475367","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627475367?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:36","pubTimestamp":1776213369,"startTime":"0","endTime":"0","summary":"证券之星消息,沃森生物04月14日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司13价肺炎结合疫苗连续多年保持国内市场份额第一,2026年在基层市场下沉和成人适应症拓展方面有哪些具体规划?同时,加强与全球健康组织和海外生物药企的交流与合作,采取多元化合作模式,持续深入推进产品在海外市场的注册和出口,保持海外业务的高质量发展态势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500008863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","300142","BK0070","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781731569954,"stockEarnings":[{"period":"1week","weight":0.0425},{"period":"1month","weight":-0.1409},{"period":"3month","weight":-0.0307},{"period":"6month","weight":0.0656},{"period":"1year","weight":0.1067},{"period":"ytd","weight":0.1037}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":-0.0057},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0559},{"period":"1year","weight":0.2128},{"period":"ytd","weight":0.0351}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"云南沃森生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"118448人(较上一季度减少0.27%)","perCapita":"13313股","listingDate":"2010-11-12","address":"云南省昆明市五华区高新区科新路395号","registeredCapital":"159934万元","survey":" 云南沃森生物技术股份有限公司的主营业务是人用疫苗等生物技术药的研发、生产和销售。公司的主要产品是13价肺炎结合疫苗、双价HPV疫苗、23价肺炎多糖疫苗、b型流感嗜血杆菌结合疫苗、A群C群脑膜炎球菌多糖结合疫苗、ACYW135群脑膜炎球菌多糖疫苗、A群C群脑膜炎球菌多糖疫苗、吸附无细胞百白破联合疫苗。公司是中国首家、全球第二家自主研发并成功上市13价肺炎结合疫苗的企业,也是中国第二家、全球第四家自主研发并成功上市HPV疫苗的企业。","listedPrice":95},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沃森生物,300142,沃森生物股票,沃森生物股票老虎,沃森生物股票老虎国际,沃森生物行情,沃森生物股票行情,沃森生物股价,沃森生物股市,沃森生物股票价格,沃森生物股票交易,沃森生物股票购买,沃森生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沃森生物(300142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沃森生物(300142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}